Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | LDHA | P00338 | 2/20 | 0.60 |
| ▸ | LDHB | P07195 | 1/20 | 0.60 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.60 |
| ▸ | STAT1 | P42224 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PHGDH | O43175 | 2/20 | 0.55 |
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396870 | 0.84 | ALDH1A1 (0.80) | KDM4ETDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL2558084 | 0.84 | KDM4E (0.73) | KDM4ETDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL28700896 | 0.84 | KDM4E (0.74) | KDM4ETDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL5963142 | 0.82 | TDP1 (0.69) | KDM4ETDP1ALDH1A1NPC1RAB9A | |
| SCHEMBL12810439 | 0.80 | KEAP1 (0.68) | KDM4ETDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL2554180 | 0.80 | POLB (1.00) | KDM4ETDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL4399339 | 0.80 | KDM4E (0.72) | KDM4ETDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL5229718 | 0.79 | KDM4E (0.67) | KDM4ETDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL622653 | 0.79 | KDM4E (0.66) | KDM4ETDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL2563465 | 0.78 | KDM4E (0.64) | KDM4ETDP1POLBALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101684115-B | 4-(5-((2-(4-morpholinyl-6-phenylamino group-1,3,5-triazine-2-base) hydrazono) methyl) furan-2-base) benzoic acid, preparing method and application thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2011-12-21 | — | — | CN | claimed |
| CN-101684115-A | 4-(5-((2-(4-morpholinyl-6-phenylamino group-1,3,5-triazine-2-base) hydrazono) methyl) furan-2-base) benzoic acid, preparing method and application thereof | SHANGHAI INST PHARM INDUSTRY | 2010-03-31 | — | — | CN | claimed |
| US-20250325542-A1 | INHIBITORS OF ANTIMOCROBIAL RESISTANCE AND METHOS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023250467-A2 | INHIBITORS OF ANTIMICROBIAL RESISTANCE AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-3684354-B1 | XPA INHIBITOR COMPOUNDS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3684354-B1 | XPA INHIBITOR COMPOUNDS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220235082-A1 | CATALYSTS | THE UNIVERSITY OF WARWICK (GB) | 2022-07-28 | — | — | US | disclosed |
| CN-114450267-A | Catalyst and process for preparing same | 贵州金之键高科技材料股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3976582-A1 | CATALYSTS | Goldenkeys High-Tech Materials Co., Ltd. (CN) | 2022-04-06 | — | — | EP | disclosed |
| US-20220089577-A1 | KU INHIBITORS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2022-03-24 | — | — | US | disclosed |
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2003081209-A2 | IDENTIFICATION OF LIGANDS FOR A RECEPTOR FAMILY AND RELATED METHODS | TRIAD THERAPEUTICS, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20030180797-A1 | Identification of ligands for a receptor family and related methods | TRIAD THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003072033-A2 | COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES | TRIAD THERAPEUTICS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-1115286-A4 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-07-23 | — | — | EP | disclosed |
| CN-1324212-A | Methods of treating or preventing viral infections and related diseases | VIROPHARMA INC (US) | 2001-11-28 | — | — | CN | disclosed |
| US-6316492-B1 | THERAPY OF INFECTION ONE VIRUS OF THE FLAVIVIRIDAE FAMILY AND DISEASE ASSOCIATED WITH SAID INFECTION BY ADMINISTERING ANTIVIRAL COMPOUND | VIROPHARMA INCORPORATED | 2001-11-13 | — | — | US | disclosed |
| EP-1115286-A1 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018231-A1 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002526-A1 | Phospholipase D inhibitors and uses thereof | PLD2, PLD1, PLA2G2D | KDM4E 2591/4885TDP1 1256/4885POLB 3477/4885 |
| US-20250325542-A1 | INHIBITORS OF ANTIMOCROBIAL RESISTANCE AND METHOS USING SAME | BPGM, PNMT, DDT | KDM4E 540/4885TDP1 1462/4885POLB 348/4885 |
| US-20220089577-A1 | KU INHIBITORS AND THEIR USE | ZFR, XRCC6, ZFX | KDM4E 581/4885TDP1 55/4885POLB 107/4885 |
| US-20220235082-A1 | CATALYSTS | TST, TCP1, CCT3 | KDM4E 1622/4885TDP1 1025/4885POLB 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.